June 2024 FDA Recall Pravastatin Sodium by Glenmark Pharmaceuticals Inc., Usa
D-0612-2024 - Failed Dissolution Specifications

This Class II drug recall was voluntarily initiated by Glenmark Pharmaceuticals Inc., Usa on June 28, 2024 for the product Pravastatin Sodium. The FDA reported the reason for recall as failed dissolution specifications. The product was distributed Nationwide and the recall is currently ongoing.

Recall Number: D-0612-2024

Reason for Recall
Failed Dissolution Specifications: results below specifications
Initiated
06-28-2024
Reported
07-24-2024
Quantity
a) 145,800 bottles; b) 1,368 bottles

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Glenmark Pharmaceuticals Inc., USA
Pravastatin Sodium Tablets, USP 80mg, packaged in a) 90-count bottle, NDC 68462-198-90; b) 500-count bottle, NDC 68462-198-05, Rx only, Manufactured by: Glenmark Pharmaceuticals Limited Pithampur, Madhya Pradesh 454775, India, Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430,

Batch or Lot Expiration Information

Lot# : a) 17211249, 17211264, 17211266,17211286, Exp 6/30/24; 17211525, 17211535, 17211549, Exp 7/31/24; 17211787, 17211801, 8/31/24; 17212041, 9/30/24; 17212088, 17212106, Exp 10/31/24; 17212346, 17212345, 11/30/24; 17220053, 17220054, 17220055 12/31/24; 17220309, 17220310, Exp 1/31/25; b) 17211290, 6/30/2024